Duration of adjuvant chemotherapy for stage III colon cancer.
dc.contributor.author | Grothey, A | |
dc.contributor.author | Sobrero, A | |
dc.contributor.author | Shields, A | |
dc.contributor.author | Yoshino, T | |
dc.contributor.author | Paul, J | |
dc.contributor.author | Taieb, J | |
dc.contributor.author | Souglakos, J | |
dc.contributor.author | Shi, Q | |
dc.contributor.author | Kerr, R | |
dc.contributor.author | Labianca, R | |
dc.contributor.author | Meyerhardt, J | |
dc.contributor.author | Vernerey, D | |
dc.contributor.author | Yamanaka, T | |
dc.contributor.author | Boukovinas, I | |
dc.contributor.author | Meyers, J | |
dc.contributor.author | Renfro, L | |
dc.contributor.author | Niedzwiecki, D | |
dc.contributor.author | Watanabe, T | |
dc.contributor.author | Torri, V | |
dc.contributor.author | Saunders, Mark P | |
dc.contributor.author | Sargent, D | |
dc.contributor.author | Andre, T | |
dc.contributor.author | Iveson, T | |
dc.date.accessioned | 2018-04-30T21:01:46Z | |
dc.date.available | 2018-04-30T21:01:46Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Duration of adjuvant chemotherapy for stage III colon cancer. 2018, 378(13): 1177-1188 N Engl J Med | en |
dc.identifier.issn | 1533-4406 | |
dc.identifier.pmid | 29590544 | |
dc.identifier.doi | 10.1056/NEJMoa1713709 | |
dc.identifier.uri | http://hdl.handle.net/10541/620929 | |
dc.description.abstract | Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer. However, since oxaliplatin is associated with cumulative neurotoxicity, a shorter duration of therapy could spare toxic effects and health expenditures. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to The New England journal of medicine | en |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Aged, 80 and over | |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject.mesh | Capecitabine | |
dc.subject.mesh | Chemotherapy, Adjuvant | |
dc.subject.mesh | Clinical Trials, Phase III as Topic | |
dc.subject.mesh | Colonic Neoplasms | |
dc.subject.mesh | Disease-Free Survival | |
dc.subject.mesh | Drug Administration Schedule | |
dc.subject.mesh | Female | |
dc.subject.mesh | Fluorouracil | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Intention to Treat Analysis | |
dc.subject.mesh | Leucovorin | |
dc.subject.mesh | Male | |
dc.subject.mesh | Medication Adherence | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Neoplasm Recurrence, Local | |
dc.subject.mesh | Neoplasm Staging | |
dc.subject.mesh | Nervous System Diseases | |
dc.subject.mesh | Organoplatinum Compounds | |
dc.subject.mesh | Proportional Hazards Models | |
dc.subject.mesh | Prospective Studies | |
dc.subject.mesh | Randomized Controlled Trials as Topic | |
dc.subject.mesh | Young Adult | |
dc.title | Duration of adjuvant chemotherapy for stage III colon cancer. | en |
dc.type | Article | en |
dc.contributor.department | Medical Oncology, Mayo Clinic, Rochester, MN | en |
dc.identifier.journal | The New England Journal of Medicine | en |
refterms.dateFOA | 2020-05-01T14:52:43Z | |
html.description.abstract | Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer. However, since oxaliplatin is associated with cumulative neurotoxicity, a shorter duration of therapy could spare toxic effects and health expenditures. |